Abstract 238P
Background
Surgery remains the cornerstone of treatment in ovarian cancers with the aim to achieve a complete cytoreduction with no macroscopic residual disease. The present study tries to assess the feasibility of laparoscopic optimal cytoreduction surgery (LOCS) in patients with advanced ovarian cancer (AOC) with low burden disease.
Methods
A retrospective study of advanced ovarian cancer that underwent LOCS between 2010 and 2014 was done. Histologically confirmed epithelial or germ cell ovarian cancer who underwent either interval or primary cytoreduction surgery were included.
Results
In all 40 patients with stage 3 ovarian cancers were included in the analysis. The median age was 50 years and the median BMI was 23 kg/m2. 39 patients had epithelial ovarian cancer (38 – serous, 1- endometrioid) and 1 patient had germ cell tumor. 23 were grade 3 and 17 were grade 2, with no patient in grade 1. Stage wise majority were stage IIIC (26 patients) followed by 3 in stage IIIA and 1 patient was stage IIIB .3 patients underwent primary cytoreduction (1- IIIA, 2- IIIB) and 37 patients received neoadjuvant chemotherapy (NACT) before surgery. 3 to 8 cycles of chemotherapy was given. On the final histopathological examination, complete response was seen in 7 patients. There was no intraoperative complication and one postoperative complication (2.5%). The median time to discharge was 5 days and the median time to start chemotherapy was 23 days. After a median follow up of 70 months 7 patients (17.5%) were lost to follow up. The overall survival was 48.3% and the recurrence-free survival was 27.2 %.19 patients recurred in the peritoneum and 5 patients had a nodal recurrence.
Conclusions
Laparoscopic cytoreduction is feasible in patients with advanced-stage ovarian cancers, provided the disease burden permits optimal debulking, especially so if done in centers with experience in complex laparoscopic procedures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
397P - Development of prediction model for hepatocellular carcinoma in chronic hepatitis B patients
Presenter: Teerapat Ungtrakul
Session: Poster display session
Resources:
Abstract
398P - Planning for future cancer control programs in Uganda: Projections of top five cancers’ incidence in the next decade
Presenter: Judith Asasira
Session: Poster display session
Resources:
Abstract
399P - Prevalence of colorectal cancer risk factors in apparently healthy adults in Suluhan Village, Bali
Presenter: Cindy Trisina
Session: Poster display session
Resources:
Abstract
400P - Female lung cancer: Emerging issue in Bangladesh
Presenter: Muhammad Rafiqul Islam
Session: Poster display session
Resources:
Abstract
402P - Work-related outcomes among cancer survivors in Singapore
Presenter: Chia Jie Tan
Session: Poster display session
Resources:
Abstract
407P - Focal treatments for metastatic soft tissue sarcoma (mSTS) is associated with improved overall survival
Presenter: Ching Tso Chen
Session: Poster display session
Resources:
Abstract
408P - The Asian sarcoma consortium sarcoma preceptorship program: A program evaluation study utilizing the Kirkpatrick model (Level 1 and 2)
Presenter: Fernando Gracieux Jr.
Session: Poster display session
Resources:
Abstract
409P - Integrated genomic and transcriptomic analysis revealed mutagenic patterns of dedifferentiated liposarcoma and leiomyosarcoma in Chinese patients
Presenter: Yuhong Zhou
Session: Poster display session
Resources:
Abstract
410P - Treatment patterns and outcomes of elderly patients with metastatic soft tissue sarcomas (mSTS)
Presenter: Yu-ju Kuo
Session: Poster display session
Resources:
Abstract
411P - Comparative analysis of protein profiles of prognosis-associated proteins and KIT-related proteins in gastrointestinal stromal tumour
Presenter: Yoshiyuki Suehara
Session: Poster display session
Resources:
Abstract